Graybiel A, Miller E F, Homick J L
Biological Sciences Department, Naval Aerospace Medical Research Laboratory, Pensacola, Florida 32512, USA.
Acta Astronaut. 1975 Jan-Feb;2(1-2):155-74. doi: 10.1016/0094-5765(75)90051-x.
One of the Skylab experiments dealt with motion sickness, comparing susceptibility in the workshop aloft with susceptibility preflight and postflight. Tests were conducted on and after mission-day 8 (MD 8) by which time the astronauts were adapted to working conditions. Stressful accelerations were generated by requiring the astronauts, with eyes covered, to execute standardized head movements (front, back, left, and right) while in a chair that could be rotated at angular velocities up to 30 rpm. The selected endpoint was either 150 discrete head movements or a very mild level of motion sickness. In all rotation experiments aloft, the five astronauts tested (astronaut 1 did not participate) were virtually symptom free, thus demonstrating lower susceptibility aloft than in preflight and postflight tests on the ground when symptoms were always elicited. Inasmuch as the eyes were covered and the canalicular stimuli were the same aloft as on the ground, it would appear that lifting the stimulus to the otolith organs due to gravity was an important factor in reducing susceptibility to motion sickness even though the transient stimuli generated under the test conditions were substantial and abnormal in pattern. Some of the astronauts experienced motion sickness under operational conditions aloft or after splashdown, but attention is centered chiefly on symptoms manifested in zero gravity. None of the Skylab-II crew (astronauts 1 to 3) was motion sick aloft. Astronaut 6 of the Skylab-III crew (astronauts 4 to 6) experienced motion sickness within an hour after transition into orbit; this constitutes the earliest such diagnosis on record under orbital flight conditions. The eliciting stimuli were associated with head and body movements, and astronaut 6 obtained relief by avoiding such movements and by one dose of the drug combination 1-scopolamine 0.35 mg + d-amphetamine 5.0 mg. All three astronauts of Skylab-III experienced motion sickness in the workshop where astronaut 6 was most susceptible and astronaut 4, least susceptible. The higher susceptibility of SL-III crewmen in the workshop, as compared with SL-II crewmen, may be attributable to the fact that they were based in the command module less than one-third as long as SL-II crewmen. The unnatural movements, often resembling acrobatics, permitted in the open spaces of the workshop revealed the great potentialities in weightlessness for generating complex interactions of abnormal or unusual vestibular and visual stimuli. Symptoms were controlled by body restraint and by drugs, but high susceptibility to motion sickness persisted for 3 days and probably much longer; restoration was complete on MD 7. From the foregoing statements it is clear that on and after MD 8 the susceptibility of SL-II and SL-III crewmen to motion sickness under experimental conditions was indistinguishable. The role played by the acquisition of adaptation effects prior to MD 8 is less clear and is a subject to be discussed.
“天空实验室”的一项实验涉及晕动病,比较了在高空工作间的易感性与飞行前和飞行后的易感性。在任务日8(MD 8)及之后进行了测试,此时宇航员已适应工作条件。通过要求宇航员在可旋转至最高30转/分钟角速度的椅子上,蒙上眼睛执行标准化的头部运动(前后、左右)来产生应激加速度。选定的终点是150次离散的头部运动或非常轻微程度的晕动病。在所有高空旋转实验中,接受测试的五名宇航员(宇航员1未参与)几乎没有症状,因此表明在高空的易感性低于在地面进行的飞行前和飞行后测试,在地面测试时总是会引发症状。由于蒙上了眼睛且高空的耳石器刺激与地面相同,尽管测试条件下产生的瞬态刺激很大且模式异常,但因重力对耳石器器官的刺激增加似乎是降低晕动病易感性的一个重要因素。一些宇航员在高空操作条件下或溅落之后出现了晕动病,但注意力主要集中在零重力下表现出的症状。“天空实验室二号”的机组人员(宇航员1至3)在高空均未患晕动病。“天空实验室三号”的机组人员(宇航员4至6)中的宇航员6在进入轨道后一小时内出现了晕动病;这是轨道飞行条件下有记录以来最早的此类诊断。引发症状的刺激与头部和身体运动有关,宇航员6通过避免此类运动和服用一剂药物组合(东莨菪碱0.35毫克 + 右旋苯丙胺5.0毫克)得到了缓解。“天空实验室三号”的所有三名宇航员在工作间都出现了晕动病,其中宇航员6最易患病,宇航员4最不易患病。与“天空实验室二号”的机组人员相比,“天空实验室三号”的机组人员在工作间的易感性较高,可能是因为他们在指令舱中的停留时间不到“天空实验室二号”机组人员的三分之一。在工作间开放空间允许的不自然运动,常常类似杂技,揭示了失重状态下产生异常或不寻常的前庭和视觉刺激复杂相互作用的巨大潜力。症状通过身体约束和药物得到控制,但对晕动病的高易感性持续了3天,可能更长;在MD 7时完全恢复。从上述陈述可以清楚地看出,在MD 8及之后,“天空实验室二号”和“天空实验室三号”机组人员在实验条件下对晕动病的易感性没有区别。在MD 8之前获得适应效果所起的作用不太清楚,是一个有待讨论的问题。